Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies

LAS VEGAS, June 17, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that screenings for diabetic retinopathy begin this week in collaboration with Grupo Dökka and its leading pharmacy subsidiaries, Fischel Pharmacies and La Bomba Pharmacies located in Central America.
Both Fischel and La Bomba Pharmacies have asked their diabetic customers to schedule a free screening as part of a collaborative program where Ainnova will use its cutting-edge AI platform, Vision AI, to help identify changes in the retina using a quick and non-invasive scan of the patient's retina.
Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., a joint venture company created by both Avant and Ainnova, said of the benefits for the collaboration, "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment—connecting every step of the journey. We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive: the well-being of the diabetic patient. Projects like this allow us to validate the model across diverse populations and sectors as part of our strategy to reach the market in a smarter, more efficient way—where the biggest winners are the patients."
Diabetic retinopathy is one of the main causes of vision loss in people with diabetes. Although, in its early stages, it may not present symptoms, it can be detected with a simple and quick screening. The screenings are important for:
Prevention: Screenings will detect changes in the retina before they affect vision.
Speed: Each screening takes only a few minutes.
Peace of Mind: Patients will receive the results of the screening in a secure and timely manner.
Grupo Dökka, which operates in Costa Rica, Nicaragua, and Panama with expansion expected into other Central American countries, has created numerous innovative platforms, including storage and distribution, pharmacies, and marketing and sales, that provide access to comprehensive health and well-being solutions for all people.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Cision Canada

9 hours ago

• Cision Canada

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Winnipeg Free Press

11 hours ago

• Winnipeg Free Press

NASA spacecraft around the moon photographs the crash site of a Japanese company's lunar lander

CAPE CANAVERAL, Fla. (AP) — A NASA spacecraft around the moon has photographed the crash site of a Japanese company's lunar lander. NASA released the pictures Friday, two weeks after ispace's lander slammed into the moon. The images show a dark smudge where the lander, named Resilience, and its mini rover crashed into Mare Frigoris or Sea of Cold, a volcanic region in the moon's far north. A faint halo around the area was formed by the lunar dirt kicked up by the impact. NASA's Lunar Reconnaissance Orbiter captured the scene last week. The crash was the second failure in two years for Tokyo-based ispace. Company officials plan to hold a news conference next week to explain what doomed the latest mission, launched from Cape Canaveral in January. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Globe and Mail

15 hours ago

• Globe and Mail

GreetEat Corp. (OTC: GEAT) Taps Neva IT to Build Salesforce Integration for Virtual Dining Experiences

RENO, Nev. , June 20, 2025 (GLOBE NEWSWIRE) -- GreetEat Corp. (OTC: GEAT), the trailblazing platform fusing video conferencing with food delivery, today announced a strategic partnership with enterprise IT leader Neva IT to develop a custom Salesforce integration for its virtual dining platform. The integration will allow Salesforce users to seamlessly plan, manage, and measure GreetEat-powered events such as client lunches, team celebrations, and virtual happy hours without ever leaving their CRM. Key features will include automated invitations, real-time voucher tracking, and ROI analytics for meetings enhanced with meals and drinks. 'Partnering with Neva IT and Bonita Elevario is a game-changer for our enterprise clients,' said Vishal Patel, CEO of GreetEat. 'This Salesforce integration will help companies elevate their virtual engagement with measurable, human-centered experiences.' With over 25 years of experience and a portfolio of Fortune 500 clients, Neva IT brings deep expertise in building secure, scalable CRM solutions. 'GreetEat is redefining how companies connect,' said Bonita Elevario, CEO of Neva IT. 'We're thrilled to help embed that experience directly into Salesforce.' Why Salesforce? As the world's leading CRM platform, Salesforce is trusted by over 150,000 companies. By integrating GreetEat into Salesforce, enterprises can simplify workflows and track the full impact of food-enhanced virtual meetings. Enterprise-Grade Security The integration will adhere to stringent security protocols, including encrypted API access, permission-based controls, and full event logging to protect user and corporate data. A Strategic Leap Forward This partnership marks a pivotal step in GreetEat's enterprise evolution—bringing the power of shared virtual dining to the global Salesforce ecosystem. About GreetEat Corp. GreetEat Corp. (OTC: GEAT) is reimagining how people connect through its virtual dining platform, which merges food delivery with real-time video conferencing for more meaningful remote interactions. About Neva IT Neva IT is a boutique technology firm specializing in enterprise-grade solutions, particularly Salesforce development, with a track record of delivering innovation to leading global organizations.